Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Avidity Biosciences Inc’s stock clocked out at $28.4, down -2.17% from its previous closing price of $29.03. In other words, the price has decreased by -$2.17 from its previous closing price. On the day, 0.91 million shares were traded. RNA stock price reached its highest trading level at $29.733 during the session, while it also had its lowest trading level at $28.38.
Ratios:
To gain a deeper understanding of RNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.91 and its Current Ratio is at 16.91. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Bernstein on June 24, 2025, initiated with a Outperform rating and assigned the stock a target price of $50.
On June 17, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $55.
On June 11, 2025, Raymond James started tracking the stock assigning a Strong Buy rating and target price of $65.Raymond James initiated its Strong Buy rating on June 11, 2025, with a $65 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 17 ’25 when Gallagher Kathleen P. sold 911 shares for $30.24 per share. The transaction valued at 27,549 led to the insider holds 50,392 shares of the business.
KATHLEEN GALLAGHER bought 911 shares of RNA for $27,148 on Jun 17 ’25. On Jun 11 ’25, another insider, Flanagan W. Michael, who serves as the Chief Scientific Officer of the company, sold 20,000 shares for $32.88 each. As a result, the insider received 657,694 and left with 80,195 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 3422767872 and an Enterprise Value of 2049386368. For the stock, the TTM Price-to-Sale (P/S) ratio is 383.35 while its Price-to-Book (P/B) ratio in mrq is 2.58. Its current Enterprise Value per Revenue stands at 229.572 whereas that against EBITDA is -4.762.
Stock Price History:
The Beta on a monthly basis for RNA is 0.92, which has changed by -0.26804125 over the last 52 weeks, in comparison to a change of 0.12632763 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $21.51. The 50-Day Moving Average of the stock is -7.39%, while the 200-Day Moving Average is calculated to be -18.83%.
Shares Statistics:
It appears that RNA traded 1.54M shares on average per day over the past three months and 1152830 shares per day over the past ten days. A total of 120.51M shares are outstanding, with a floating share count of 109.84M. Insiders hold about 8.87% of the company’s shares, while institutions hold 107.71% stake in the company. Shares short for RNA as of 1749772800 were 16344285 with a Short Ratio of 10.62, compared to 1747267200 on 15787027. Therefore, it implies a Short% of Shares Outstanding of 16344285 and a Short% of Float of 13.69.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
